Table 1.
Characteristics of observed AF patient samples
| Characteristics | All observed AF-patients | Unmatched
|
PS-matched
|
||||
|---|---|---|---|---|---|---|---|
| Cohort 1 (NOAC) | Cohort 2 (VKA) | Cohort 1 versus 2 (p-value) | Cohort 1 (NOAC) | Cohort 2 (VKA) | Cohort 1 versus 2 (p-value) | ||
| N | 483,149 | 51,155 | 128,274 | – | 37,439 | 37,439 | – |
| Mean follow-up time since index date (SD); median | – | 341.2 days (245.29); 290 | 393.1 days (311.30); 239 | p<0.001 | 348.5 days (247.57); 299 | 365.5 days (290.74); 197 | p>0.100 |
| Mean age in years (SD) | 76.24 (13.33) | 78.21 (8.56) | 76.61 (8.34) | p<0.001 | 78.21 (7.40) | 78.16 (7.37) | p>0.100 |
| Gender; Female N (%) | 253,750 (52.52) | 26,519 (51.84) | 66,112 (51.54) | p>0.100 | 19,659 (52.51) | 19,622 (52.41) | p>0.100 |
| Mean CCI without age factor (SD) | 3.56 (2.79) | 5.09 (2.74) | 4.45 (2.46) | p<0.001 | 4.78 (2.60) | 4.80 (2.55) | P<0.500 |
| Mean CHA2DS2 VASc score (SD) | 2.47 (1.54) | 3.09 (1.09) | 2.88 (1.00) | p<0.001 | 2.96 (1.04) | 2.95 (1.03) | p>0.100 |
| Prescribed DDDs of study medicationa | NA | 1.21 (1.97) | 0.81 (1.67) | – | 1.19 (1.87) | 0.82 (1.80) | – |
| Prescribed DDDs of Heparins or Clopidogrelb | NA | 3.27 (21.20) | 3.32 (13.12) | p<0.001 | 3.16 (22.22) | 3.67 (16.66) | p<0.001 |
Notes: The table lists sociodemographic characteristics for the different observed AF patient samples. These data refer to patient-specific index dates for age/gender and to the 12-month baseline period before index date. The date of the first prescription of a NOAC/VKA agent in the inclusion period was used as the index date.
(NOAC/VKA) per observed patient day during follow-up period;
Per observed patient month. CHA2DSs Vasc (congestive heart failure, hypertension, age, diabetes, previous stroke/transient ischemic attack, and Vascular disease). “–” indicates not calculated.
Abbreviations: CCI, Charlson comorbidity index; DDD, defined daily dosage; NA, not applicable; NOAC, non-vitamin K antagonist oral anticoagulants; PS, propensity score; VKA, vitamin-K-antagonist.